Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. It offers Trokendi XR, Oxtellar XR, APOKYN, XADAGO, and MYOBLOC products. The company was founded by Jack A. Khattar on March 30, 2005 and is headquartered in Rockville, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Supernus Pharmaceuticals achieves record revenues, faces generic competition in 2022

Supernus Pharmaceuticals delivered a strong financial performance in 2022, driven by record revenues and successful product launches.
While facing challenges from generic competition, the company's focus on growth brands and pipeline assets offers opportunities for future expansion and innovation.
Strategic financial management and market adaptation will be crucial for Supernus Pharmaceuticals to navigate challenges and capitalize on growth prospects in 2023.
With a solid financial foundation and a commitment to innovation, the company is poised to pursue growth opportunities and enhance shareholder value in the pharmaceutical sector.

Supernus Pharmaceuticals reports Q1 revenue growth, faces Trokendi XR challenges

Supernus Pharmaceuticals delivered a mixed performance in Q1 2023, with strong revenue but challenges in Trokendi XR sales.
The company's financial strength, strategic guidance revisions, and pipeline progress position it for future growth.
Opportunities lie in leveraging cash reserves, driving key product sales, and advancing pipeline programs for sustained growth.
Addressing challenges in Trokendi XR sales and maintaining competitive positioning will be crucial for Supernus Pharmaceuticals' success.

Supernus Pharmaceuticals reports Q2 growth driven by Qelbree success

Supernus Pharmaceuticals showcased strong performance in Q2 2023, driven by Qelbree and GOCOVRI growth, despite Trokendi XR sales decline.
While facing challenges with Trokendi XR, the company's pipeline progress and strategic focus on key products offer growth opportunities.
Management's financial guidance reiteration for 2023 reflects confidence in the company's ability to navigate challenges and capitalize on strengths.
Overall, Supernus Pharmaceuticals remains positioned for growth through product innovation and market expansion strategies.

Supernus Pharmaceuticals reports robust Q3 performance amidst revenue challenges

Supernus Pharmaceuticals delivered a strong performance in Q3 2023 driven by Qelbree and GOCOVRI, showcasing revenue growth and promising product milestones.
While facing challenges with Trokendi XR sales decline and financial losses, the company maintains a positive outlook with revised full-year guidance and a solid cash position.
Opportunities lie in leveraging product strengths, advancing pipeline studies, and utilizing available resources to sustain growth and navigate challenges effectively.

Supernus Pharmaceuticals reports robust earnings, eyes CNS market expansion

Supernus Pharmaceuticals delivered strong financial performance in Q4 2023 and full year 2023, supported by record sales and stable earnings.
The company's transition to growth products, strong cash reserves, and strategic focus on CNS present a promising outlook for future growth.
While challenges exist in product transitions and market dynamics, Supernus is well-positioned to capitalize on opportunities in the CNS space.
By leveraging its strengths, addressing challenges, and seizing opportunities, Supernus Pharmaceuticals aims for sustained growth and market leadership.

Supernus Pharmaceuticals reports robust Q1 performance amidst pipeline opportunities

Supernus Pharmaceuticals demonstrated strong performance in Q1 2024, driven by Qelbree's growth, while facing challenges in the Parkinson's franchise.
The company's financial stability is evident with a healthy cash position and reiterated full-year revenue guidance.
Exciting opportunities exist in the CNS pipeline, but addressing setbacks like the FDA response for SPN-830 is crucial.
Strategic actions are needed to navigate the impact of generics on existing products and capitalize on upcoming catalysts.

Supernus Pharmaceuticals reports strong Q2 earnings and raises 2024 guidance

Supernus Pharmaceuticals demonstrated solid financial performance and growth in Q2 2024, driven by key products and pipeline advancements.
While facing regulatory uncertainties and operational challenges, the company's strong cash position and raised guidance signal resilience and strategic foresight.
Opportunities lie in expanding the CNS pipeline, optimizing gross-to-net deductions, and leveraging financial strength for future growth initiatives.

Supernus Pharmaceuticals reports strong Q3 performance and raises revenue guidance

Supernus Pharmaceuticals demonstrated robust financial performance and product growth in Q3 2024, driven by key products and pipeline advancements.
While facing challenges with certain product sales and pricing strategies, the company remains well-positioned for future opportunities and revenue expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. It offers Trokendi XR, Oxtellar XR, APOKYN, XADAGO, and MYOBLOC products. The company was founded by Jack A. Khattar on March 30, 2005, and is headquartered in Rockville, MD.

A Super 'Pick-Up' By Supernus

ROCKVILLE, Md., April  28, 2020  (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company entered into a definitive agreement under which Supernus will acquire the CNS portfolio of US WorldMeds, a privately-held biopharmaceutical company. With the acquisition, Supernus adds three established and marketed products in the U.S. market with a product candidate in late-stage development:

Supernus to Acquire CNS Portfolio from US WorldMeds

Karyopharm Therapeutics

These two underrated biotech stocks have the potential to soar.

Your 2 Top Profit Opportunities in 2020

ROCKVILLE, Md. and CAMBRIDGE, Mass., April  21, 2020  (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, and Navitor Pharmaceuticals, Inc., a privately-held company leading the discovery and development of mTORC1-targeted therapeutics, announced today a joint development and option agreement for Navitor’s mTORC1 activator, NV-5138.

Supernus and Navitor Announce Development and Option Agreement for Orally Active mTORC1 Activator NV-5138

ROCKVILLE, Md., March  30, 2020  (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today provides a business update related to the COVID-19 situation.

Supernus Provides Business Update

Jazz Pharmaceuticals

Seelos Therapeutics

Jazz Pharma's Mixed Earnings, And Other News: The Good, Bad And Ugly Of Biopharma

Shares slumped after the commercial-stage biopharma reported mixed results.

Why Supernus Pharmaceuticals Plunged 15% Today

Supernus Pharmaceuticals, Inc. (SUPN) CEO Jack Khattar on Q4 2019 Results - Earnings Call Transcript

Supernus (SUPN) delivered earnings and revenue surprises of 8.77% and -6.36%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Supernus Pharmaceuticals (SUPN) Q4 Earnings Beat Estimates

SPN-812 (viloxazine hydrochloride), a once-daily novel serotonin norepinephrine modulating agent (SNMA), demonstrates a reduction in ADHD-RS-5 total score as early as Week 1 and continuing until the end of the pivotal clinical studies SPN-812 (viloxazine hydrochloride), a once-daily novel serotonin norepinephrine modulating agent (SNMA), demonstrates a reduction in ADHD-RS-5 total score as early as Week 1 and continuing until the end of the pivotal clinical studies

Supernus Announces FDA Acceptance for Review of New Drug Application for SPN-812 for the Treatment of ADHD

Is Supernus Pharmaceuticals (SUPN) a great pick from the value investor's perspective right now? Read on to know more.

Can Value Investors Pick Supernus Pharmaceuticals (SUPN) Stock?

ROCKVILLE, Md., Dec.  09, 2019  (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, is providing an update on the results from the first Phase III study (P301) of SPN-810, a novel treatment of Impulsive Aggression (IA) in patients with ADHD.

Supernus Provides Update on Results from Phase III Study (P301) of SPN-810 for Treatment of Impulsive Aggression (IA) in ADHD Patients

SPN-812 (viloxazine hydrochloride), a novel serotonin norepinephrine modulating agent (SNMA) SPN-812 (viloxazine hydrochloride), a novel serotonin norepinephrine modulating agent (SNMA)

Supernus Submits New Drug Application for SPN-812 for the Treatment of ADHD

Supernus Pharmaceuticals, Inc. (SUPN) CEO Jack Khattar on Q3 2019 Results - Earnings Call Transcript

Supernus (SUPN) delivered earnings and revenue surprises of -8.47% and -6.51%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Supernus Pharmaceuticals (SUPN) Q3 Earnings and Revenues Lag Estimates

Supernus (SUPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Supernus Pharmaceuticals (SUPN) Reports Next Week: Wall Street Expects Earnings Growth

Today, we revisit Supernus Pharmaceuticals, whose stock is down just over 30% from highs earlier in the year.

Supernus Pharmaceuticals: Solid Bet Into Year End

ROCKVILLE, Md., Sept.  25, 2019  (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that the Company's management will present a Company overview and update, as well as host investor meetings, at the 2019 Cantor Global Healthcare conference:

Supernus to Present at the 2019 Cantor Global Healthcare Conference

Atrion

Corcept Therapeutics

Merit Medical Systems

National Research Corp

According to the GuruFocus All-In-One Screener as of Friday, the following health care stocks are popular among gurus.

5 Health Care Stocks - Gurus Are Buying

President, CEO of Supernus Pharmaceuticals Inc (30-Year Financial, Insider Trades) Jack A.

Supernus Pharmaceuticals Inc (SUPN) President, CEO Jack A. Khattar Bought $190,008 of Shares

ROCKVILLE, Md., Aug.  26, 2019  (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that the Company's management will present a Company overview and update, as well as host investor meetings, at the following September conferences:

Supernus to Present at Two September Healthcare Conferences

Supernus pharmaceuticals was founded in 2005 and was previously a subsidiary of Shire PLC. SUPN and its management team have developed and commercialized central nervous system ("CNS") products for more than 25 years.

Supernus Pharmaceuticals: Anti-CGRPs Are Causing Migraines For This Biotech But Investors Are Too Pessimistic Creating A Compelling Opportunity

Let's see if Supernus Pharmaceuticals (SUPN) stock is a good choice for value-oriented investors right now from multiple angles.

Can Value Investors Pick Supernus Pharmaceuticals (SUPN)?

Supernus Pharmaceuticals, Inc. (SUPN) CEO Jack Khattar on Q2 2019 Results - Earnings Call Transcript

Supernus (SUPN) delivered earnings and revenue surprises of 8.93% and -3.70%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

News for Supernus Pharmaceuticals Stock (SUPN)